Le Lézard
Classified in: Health, Science and technology

CerSci Therapeutics Awarded Phase I STTR Grant From the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to Test Feasibility of a New Therapeutic Approach to Treat Migraine


DALLAS, Aug. 21, 2018 /PRNewswire/ -- CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas has received notice from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) that it has been awarded a Phase I Small Business Technology Transfer (STTR) grant totaling over $220,000. These funds will support the preclinical development of novel, proprietary small-molecules for the treatment of migraine.

Dr. Scott L. Dax, CerSci Chief Scientific Officer, commented that the company is extremely grateful for continued support from the NIH which helps "to fuel the CerSci mission of developing new therapeutics to treat pain by thwarting processes that lead to neuronal sensitization. We are especially thrilled to have Professor Greg Dussor leading this project given his renowned expertise in the area of migraine." 

Professor Dussor, added that "It has been known for over 170 years that nitric oxide-generating drugs like nitroglycerin reliably trigger migraines in humans. This observation strongly suggests a role for nitric oxide and its downstream products in migraine pathology.  The CerSci platform is uniquely positioned to explore nitric oxide-initiated pathways that lead to the onset of migraine, and to develop new drugs to prevent or treat the attacks that afflict and disable millions of people, primarily females." 

"Funding of this proposal further validates the science we conduct at CerSci Therapeutics and will expand our 'footprint' in pain research, as we broaden our pipeline from acute use products to replace opioids, to drugs that will manage chronic neuropathies, and now focus on drugs for migraine," stated CerSci Chief Executive Officer, Dr. Lucas Rodriguez.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About CerSci Therapeutics
CerSci Therapeutics is dedicated to pharmaceutical research and development in the area of non-opioid therapeutics for the alleviation of acute and chronic pain.

Media Contact:
Eugene Garza
+1 (214) 306-6218
[email protected]  
www.CerSci.com

SOURCE CerSci Therapeutics


These press releases may also interest you

at 15:12
Health insurers are doing our part to reduce the admin burden on family doctors
The Canadian Life and Health Insurance Association (CLHIA) supports the steps announced by the Ontario government yesterday to help family doctors and other primary care providers spend more time with their patients and less time on paperwork. "Our...

at 15:05
Spellerstm Method Launches TV Series For Autism Awareness
On May 26, Dawnmarie Gaivin and Dana Johnson, founders of the Spellers Methodtm used by thousands of nonspeaking individuals with autism, in partnership with filmmaker Pat R. Notaro III, will launch a video-on-demand docuseries that chronicles what...

at 14:53
Erie Insurance receives Business Group on Health's 'Best Employers: Excellence in Health & Well-being' award
Erie Insurance (ERIE) has received the 2024 Best Employers: Excellence in Health & Well-being award from Business Group on Health. The annual corporate awards program recognizes companies across diverse sectors for advancing employee well-being...

at 14:41
Cartessa Aesthetics Unveils PHYSIQ 360, A Revolutionary Non-Invasive Body Contouring Treatment
Cartessa Aesthetics, a premier North American aesthetic medical device company, launches PHYSIQ 360, a groundbreaking technology that elevates non-invasive body contouring. PHYSIQ 360 is the next generation of the award-winning PHYSIQ body technology...

at 14:37
Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of...

at 14:34
ISS National Lab-Sponsored Research Could Produce Nanomaterials for Life-Saving Therapies and Precision Drug Delivery
Arthritis is a crippling disease, affecting approximately one in four adults. It wreaks havoc on our joints by breaking down cartilage, the cushioning between bones. Once that cartilage deteriorates, there's no way to replace it. However, all this...

More news about Health...


News published on and distributed by: